Medication info
Mediya Tablet (Glimepiride)

Mediya Tablet (Glimepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
Shinil Pharmaceutical Co., Ltd.
Appearance
Green oblong tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200402602 · Notified 2004.02.02 · Insurance code 653800630

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose determination For patients who have not previously received drug therapy, begin treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1–2 weeks. Generally, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control may improve during treatment, the amount of this medicine needed may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is recommended that the method described under Initial dose be followed. That is, start with 1 mg daily and adjust the dose at 1–2-week intervals. The potency and duration of action of the previous medicine should be taken into account. 4) Dose monitoring and adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after it has initially been successfully managed during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal; start insulin at a low dose and increase it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, the addition of metformin may be considered. Published clinical information is available on combination therapy with metformin and other sulfonylureas, such as glyburide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
Shinil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to enhance blood sugar control in patients with type 2 diabetes. It can be administered alone as an adjunct to dietary management and exercise, and is effective even when used in combination with oral hypoglycemic agents or insulin when blood sugar control is difficult. Additionally, when blood sugar control is inadequate with monotherapy using sulfonylureas or metformin, it is administered in combination with metformin to improve blood sugar management. This medication helps to stabilize blood sugar levels, thus aiding the patient's health.

How to take

Adult dose

Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose determination For patients who have not previously received drug therapy, begin treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1–2 weeks. Generally, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control may improve during treatment, the amount of this medicine needed may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is recommended that the method described under Initial dose be followed. That is, start with 1 mg daily and adjust the dose at 1–2-week intervals. The potency and duration of action of the previous medicine should be taken into account. 4) Dose monitoring and adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after it has initially been successfully managed during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal; start insulin at a low dose and increase it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, the addition of metformin may be considered. Published clinical information is available on combination therapy with metformin and other sulfonylureas, such as glyburide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be administered to patients with insulin-dependent diabetes or diabetic ketoacidosis. Patients who have had allergic reactions to this medication or its components should not use it. In patients with severe liver or kidney function impairment, switching to insulin therapy is recommended instead of using this medication. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. Patients with severe infections, pre- or post-surgery, or significant trauma are advised to use insulin therapy. In cases of gastrointestinal disturbances such as diarrhea or vomiting, there is a risk of hypoglycemia due to poor food absorption, so caution should be exercised. This medication contains lactose and should not be administered to patients with lactose intolerance or certain genetic metabolic disorders. There is a high risk of hypoglycemia during the first week of dosing, so blood sugar should be monitored carefully. Particularly, elderly patients, those with poor nutritional status or irregular eating habits, and individuals who consume alcohol frequently are more susceptible to hypoglycemia. Caution is also required if there is an imbalance in physical activity and carbohydrate intake or changes in meal patterns. Patients with weakened kidney or liver function or those who have overdosed on other medications also have an increased risk of hypoglycemia. Also, elderly patients with endocrine disorders such as thyroid abnormalities or adrenal insufficiency, and those on certain medications such as beta-blockers, should be monitored carefully. Additionally, careful observation is necessary when used in combination with drugs that could affect blood sugar control. This medication may cause symptoms of hypoglycemia. Symptoms of hypoglycemia include headache, severe hunger, nausea, fatigue, anxiety, decreased concentration, confusion, drowsiness, and in severe cases, loss of consciousness or coma. In cases of hypoglycemia, it is crucial to immediately consume food containing sugar or seek medical assistance for treatment. Temporary blurred vision, gastrointestinal disturbances, liver dysfunction, blood abnormalities, or allergic reactions may occur during the initial stages of treatment. Consultation with a physician is necessary if any adverse symptoms occur. It is vital to regulate blood sugar well by taking this medication regularly along with dietary and exercise programs. To prevent hypoglycemia, always keep food containing sugar on hand, and be aware of hypoglycemia symptoms and treatment methods. In situations of stress, surgery, or infection that make blood sugar control difficult, temporary switching to insulin therapy may be necessary. Regular blood sugar and urinary sugar tests should be performed to verify medication effectiveness and adjust treatment methods as needed. This medication is excreted through the kidneys, so elderly patients or those with decreased kidney function should take care with dosage adjustments. In case of overdose, severe hypoglycemia may manifest, and appropriate treatment should be sought immediately at a medical facility.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disorders, anxiety, aggression, decreased concentration, decreased agility or energy, depression, confusion, language abnormalities, aphasia, visual impairment, tremors, incomplete paralysis, perceptual abnormalities, dizziness, weakness, loss of self-control, temporary mental confusion, convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, venous arrhythmia, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis, pancytopenia, itching, hives, rash, dyspnea, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, photosensitivity reactions, decreased serum sodium concentration, taste disturbances, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, dyspepsia, facial edema, erectile dysfunction, facial flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage can help retain the medication's efficacy for a longer time.

Appearance and packaging

Appearance

Green oblong tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.